Inhibitory effect of troglitazone on tumor necrosis factor alpha-induced expression of monocyte chemoattractant protein-1 in human mesangial cells

Metabolism: Clinical and Experimental

Volumn 49, Issue 2, 2000, Pages 163-166

  Ohta, Masayoshi Y ^a   Nagai, Yukihiro ^a   Takamura, Toshinari ^a   Nohara, Erika ^a   Kobayashi, Ken Ichi ^a  

^a KANAZAWA UNIV SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; TROGLITAZONE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; ATHEROSCLEROSIS; CELL MIGRATION; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; INSULIN RESISTANCE; MESANGIUM CELL; NORTHERN BLOTTING; PRIORITY JOURNAL;

EID: 0033961164     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0026-0495(00)91143-0     Document Type: Article

References (31)

1. Reaven GM Role of insulin resistance in human disease Diabetes 37 1988 1595 1607
2. Moller DE Flier JS Insulin resistance: Mechanisms, syndromes and implications N Engl J Med 324 1991 938 948
3. Dzurik R Spustova V Janekova K The prevalence of insulin resistance in kidney disease patients before the development of renal failure Nephron 69 1995 281 285
4. Kumar S Boulton AJM Beck-Nielsen H Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients Diabetologia 39 1996 701 709
5. Nagasaka Y Kaku K Nakamura K The new oral hypoglycemic agent, CS-045, inhibits the lipid peroxidation of human plasma low-density lipoprotein in vitro Biochem Pharmacol 50 1995 1109 1111
6. Noguchi N Sakai H Kato Y Inhibition of oxidation of low-density lipoprotein by troglitazone Atherosclerosis 123 1996 227 234
7. Gralinski MR Rowse PE Breider MA Effects of troglitazone and pioglitazone on cytokine-mediated endothelial cell proliferatioon in vitro J Cardiovasc Pharmacol 31 1999 909 913
8. Satoh H Tsukamoto K Hashimoto Y Thiazolidinediones suppress endothelin-1 secretion from bovine vascular endothelial cells: A new possible role of PPAR on vascular endothelial function Biochem Biophys Res Commun 254 1999 757 763
9. Rollins BJ Yoshimura T Leonard EJ Cytokine-activated human endothelial cells synthesize and secrete a monocyte chemoattractnt, MCP-1/JE Am J Pathol 136 1990 1229 1233
10. Yu X Dluz S Graves DT Elevated expression of monocyte chemoattractant protein 1 by vascular smooth muscle cells in hypercholesterolemic primates Proc Natl Acad Sci USA 89 1992 6953 6957
11. Rovin BH Yoshimura T Tan L Cytokine-induced production of monocyte chemoattractant protein-1 by cultured human mesangial cells J Immunol 1 1992 2148 2153
12. Furuta T Saito T Ootake T The role of macrophages in diabetic glomerulosclerosis Am J Kidney Dis 21 1993 480 485
13. Yla-Herttuala S Lipton BA Rosenfeld ME Expression of monocyte chemoattractant protein 1 in macrophage-rich areas of human and rabbit atherosclerotic lesions Proc Natl Acad Sci USA 88 1991 5252 5256
14. Nelken NS Coughlin SR Gordon D Monocyte chemoattractant protein-1 in human atheromatous plaques J Clin Invest 88 1991 1121 1127
15. Chomczynski P Sacchi N Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction Anal Biochem 162 1987 156 159
16. Strieter RM Wiggins R Phan SH Monocyte chemotactic protein gene expression by cytokine-treated human fibroblasts and endothelial cells Biochem Biophys Res Commun 162 1989 694 700
17. Yoshimura T Yuhki N Moore SK Human monocyte chemoattractant protein-1 (MCP-1): Full-length cDNA cloning, expression in mitogen-stimulated blood monocytes leukocytes, and sequence similarity to mouse competence gene JE FEBS Lett 244 1989 487 493
18. Hotamisligil GS Peraldi P Budavaria A IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-α- and obesity-induced insulin resistance Science 271 1996 665 668
19. Stephens JM Lee J Pilch PF Tumor necrosis factor-alpha—induced insulin resistance in 3T3-L1 adipocytes is accompanied by a loss of insulin receptor substrate-1 and GLUT 4 expression without a loss of insulin receptor—mediated signal transduction J Biol Chem 272 1997 971 976
20. Lehmann JM Moore LB Smith-Oliver TA An antidiabetic thiazolidinedione is a high-affinity ligand for peroxisome proliferator—activated receptor gamma (PPAR gamma) J Biol Chem 270 1995 12953 12956
21. Okuno A Tamemoto H Tobe K Troglitazone increases the number of small adipocytes without a change of white adipose tissue mass in obese Zucker rats J Clin Invest 101 1998 1354 1361
22. Nolan JJ Ludvik B Beerdsen P Improvement in glucose tolerance and insulin resistance in obese subjects treated with torglitazone N Engl J Med 331 1994 1188 1193
23. Shiomi M Ito T Tsukada T Combination treatment with troglitazone, an insulin action enhancer, and pravastatin, an inhibitor of HMG-CoA reductase, shows a synergistic effect on atherosclerosis of WHHL rabbits Atherosclerosis 142 1999 345 353
24. Minamikawa J Tanaka S Yamauchi M Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes J Clin Endocrinol Metab 83 1998 1818 1820
25. Hattori Y Hattori S Kasai K Troglitazone upregulates nitric oxide synthesis in vascular smooth cells Hypertension 33 1999 943 948
26. Law RE Meehan WP Xi XP Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia J Clin Invest 98 1996 1897 1905
27. Fujii M Takemura R Yamaguchi M Troglitazone (CS-045) ameliorates albuminuria in streptozotocin-induced diabetic rats Metabolism 46 1997 981 983
28. Rovin BH Dickerson JA Tan LC Activation of nuclear factor-κB correlates with MCP-1 expression by human mesangial cells Kidney Int 48 1995 1263 1271
29. Jiang C Ting AT Seed B PPAR-γ agonists inhibit production of monocyte inflammatory cytokines Nature 391 1998 82 86
30. Takahara N Kashiwagi A Nishio Y Oxidized lipoproteins found in patients with NIDDM stimulate radical-induced monocyte chemoattractant protein-1 mRNA expression in cultured human endothelial cells Diabetologia 40 1997 662 670
31. Young MA Eckland DA Eastmond R Establishing the dose response curve for metabolic control with troglitazone, an insulin action enhancer, in type 2 diabetes patients Ann Med 30 1998 206 212